Following is a complete list of oncology studies currently enrolling patients. Click on a link to learn more about it.

Brain Cancer Studies

• Phase I/II Trial of Imatinib Mesylate in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma (NCCTG N0272)

Breast Cancer Studies

• A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer
• Hormone Therapy with or without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer : The TAILORx Trial (ECOG PACCT-1)
• Radiation Therapy in Treating Women Who Have Undergone Surgery for Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer (NSABP B-39/RTOG 0413)
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy (NSABP B-43)
• A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (NSABP B-46-I/USOR 07132)
• Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (ECOG E5103)
• A Randomized, Multi-Center, Open-Label, Phase II Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2-Positive Primary Breast Cancer (ALTTO N063D/BIG 2-06)
• Phase III Randomized Study of Tamoxifen Citrate or Letrozole With Versus Without Bevacizumab in Women With Hormone Receptor-Positive Stage IIIB-IV Breast Cancer (CALGB 40503)
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Denosumab as Adjuvant Treatment for Women with Early Stage Breast Cancer at High Risk of Recurrence (D-CARE Study)
• A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer at Initial Diagnosis (ACOSOG Z1071) 
• A Study of Trastuzumab-DM1 (T-DM1) Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (BO22589)
• Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer (CALGB C40603)

Colon Cancer Studies

• Randomized, Phase III Study Comparing 5-FU, Leucovorin & Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin & Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (ECOG E5202)
• Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuxmimab with or without Bevacizumab as 2nd-Line Therapy for Patients with Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX (CTSU S0600)
• Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer (ECOG E4203)
• A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab or Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (CTSU C80405)
• Statin Polyp Prevention Trial in Patients with Resected Colon Cancer (NSABP P-5)

Esophageal Cancer Studies

• A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (with the potential for crossover) for Elderly and/or Poor Performance Status Patients with Adenocarcinoma of the Esophagus or Gastroesophageal Junction (NCCTG N0747)
• Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Gastric Cardia (NCCTG N0849) 

Gynecologic Cancer Studies

• Collecting Tumor Samples from Patients with Gynecological Tumors (GOG 0136)
• Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer (GOG 0212)
• Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (GOG 0213)
• Phase III Randomized Study of Bevacizumab in Combination with Intravenous Versus Intraperitoneal Chemotherapy in Patients with Stage II or III Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Carcinoma (GOG 0252)
• A Phase II Evaluation of SU11248 (Sunitinib Malate) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma (GOG 0254)
• A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG 0256)
• A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix (GOG 0240)
• Phase II Randomized Study of Paclitaxel, Carboplatin, and Bevacizumab Versus Paclitaxel, Carboplatin, and Temsirolimus Versus Ixabepilone, Carboplatin, and Bevacizumab in Patients With Stage III-IV or Recurrent Endometrial Cancer (GOG 0086P)
• Molecular Staging of Endometrial Cancer (GOG 0210)
• A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Carcinoma (GOG 0249)
• A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel for Optimally Debulked (GOG 0258)
• A Randomized Phase III Trial of Paclitaxel plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus (GOG 0261)
• A Randomized Phase III Evaluation of Docetaxel and Gemcitabine Plus G-CSF with Bevacizumab Versus Docetaxel and Gemcitabine Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus, NCI-Supplied Agent: Bevacizumab (GOG 0250)

Head & Neck Cancer Studies

• Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (ECOG E1305)

Leukemia Studies

• Phase II Study of Combination Chemotherapy in Adolescents and Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ECOG C10403)
• Phase III Randomized, Double-blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) (CTSU C10603)
• Collecting Tissue Samples from Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial (ECOG E3903)

Lung Cancer Studies

• Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy
• A Phase II First-Line Study of a Combination of Premetrexed, Carboplatin, and Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Cancer Evaluating Efficacy and Tolerability in Elderly Patients (age ≥ 70 years) with Good Performance Status (NCCTG N0821)
• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery (ECOG E1505)
• Randomized Phase III Trial of Gemcitabine/Carboplatin with or without BSI-201 in Subjects with Previously Untreated Stage IV Squamous Non Small-Cell Lung Cancer (ECLIPSE Study)

Lymphoma Studies

• A Phase III Multi-Center, Randomized, Double-Blind, Placebo-Controlled, First-Line Maintenance Study of Lenalidomide (Revlimid) in Patients with Mantle-Cell Lymphoma

Melanoma Studies

• Phase III Randomized Adjuvant Study of High-Dose Interferon alfa-2b Therapy in Patients With Stage II or III Melanoma (ECOG E1697)

Myelodysplastic Syndrome Studies

• A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
• An Open Label Extension Study Evaluating the Safety of Long-Term Dosing of Romiplostim in Thrombocytopenic Subjects with Myelodysplastic Syndrome 

Neuroendocrine Cancer Studies

• Octreotide and Interferon alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (CTSU S0518)

Prostate Cancer Studies

• Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases (CTSU C90202)
• Phase III Randomized Study of Chemohormonal Therapy versus Androgen Ablation Therapy in Patients with Extensive Metastatic Prostate Cancer (ECOG E3805)

Rectal Cancer Studies

• Clinical Trial Comparing Pre-Op Radiation Therapy and Capecitabine with Pre-Op Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-FU in the Treatment of Patients with Operable Carcinoma of the Rectum (NSABP R-04)
• Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer (ECOG E4203)
• A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab or Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (CTSU C80405)

Renal Cancer Studies

• Randomized, Double-blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (ECOG E2805)
• A Randomized Phase II Study of VEGF, RAF Kinase and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma; The BeST Trial (ECOG E2804)
• Randomized Phase II Study to Determine the Effect of Two Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma (ECOG E4805) 

Bone Marrow Transplant Studies

• Fludarabine Based Conditioning for Allogeneic Marrow Transplantation for HLA-Compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN 0301)
• Phase II Trial of Non-Myeloablative, Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response (BMT CTN 0701)
• A Multi-Center, Randomized, Double-Blind, Phase III Trial Evaluating Corticosteroids with Mycophenolate Mofeti Versus Corticosteroids with Placebo as Initial Systemic Treatment of Acute GvHD (BMT CTN 0802)
• RDSafe: A Multi-Center Study of Hematopoietic Stem Cell Donor Safety and Quality of Life (CIBMTR 06 DON)
• Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors
• Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): a Treatment IND Study

Cancer Control Studies

• Palitaxel-Associated Acute Pain Syndrome Natural History Study (NCCTG N08C1)
• American Ginseng in Treating Patients with Fatigue Caused by Cancer (NCCTG N07C2)

Cancer Registry Studies

• The Multiple Myeloma Disease Registry for Patients with Newly-Diagnosed Symptomatic Multiple Myeloma